Who are Low dose oral anticoagulant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, No OAC, warfarin accordingly INR value, Dabigatran; Rivaroxaban, Rivaroxaban, dabigatran, apixaban, or edoxaban, Warfarin or coumadin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-oral-anticoagulant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Low dose oral anticoagulant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low dose oral anticoagulant (Low dose oral anticoagulant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral anticoagulant. Area: Cardiovascular.

marketed Oral anticoagulant Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Low dose oral anticoagulant (Low dose oral anticoagulant) — Korea University Guro Hospital. Low-dose oral anticoagulants inhibit blood coagulation factors to reduce thrombus formation while minimizing bleeding risk through reduced dosing.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low dose oral anticoagulant TARGET	Low dose oral anticoagulant	Korea University Guro Hospital	marketed	Oral anticoagulant
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
No OAC	no-oac	Pfizer	marketed	Direct Oral Anticoagulant	Factor Xa
warfarin accordingly INR value	warfarin accordingly INR value	Azienda Ospedaliera Universitaria Policlinico	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Dabigatran; Rivaroxaban	Dabigatran; Rivaroxaban	University Hospital, Grenoble	marketed	Direct oral anticoagulant (DOAC)	Dabigatran: Factor IIa (thrombin); Rivaroxaban: Factor Xa
Rivaroxaban, dabigatran, apixaban, or edoxaban	Rivaroxaban, dabigatran, apixaban, or edoxaban	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral anticoagulant class)

China National Center for Cardiovascular Diseases · 1 drug in this class
Korea University Guro Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose oral anticoagulant — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-oral-anticoagulant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab